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Telomere maintenance by telomerase activation or alternative lengthening of telomeres
(ALT) is a major determinant of poor outcome in neuroblastoma. Here, we screen for ALT in
primary and relapsed neuroblastomas (n= 760) and characterize its features using multi-
omics profiling. ALT-positive tumors are molecularly distinct from other neuroblastoma
subtypes and enriched in a population-based clinical sequencing study cohort for relapsed
cases. They display reduced ATRX/DAXX complex abundance, due to either ATRX mutations
(55%) or low protein expression. The heterochromatic histone mark H3K9me3 recognized by
ATRX is enriched at the telomeres of ALT-positive tumors. Notably, we find a high frequency
of telomeric repeat loci with a neuroblastoma ALT-specific hotspot on chr1q42.2 and loss of
the adjacent chromosomal segment forming a neo-telomere. ALT-positive neuroblastomas
proliferate slowly, which is reflected by a protracted clinical course of disease. Nevertheless,
children with an ALT-positive neuroblastoma have dismal outcome.
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Activation of a telomere maintenance mechanism (TMM)was found to be associated with poor outcome in neu-roblastoma1, which is the most common extracranial solid
tumor diagnosed in early childhood2–5. Telomerase activation is
one way of maintaining telomere length and results from
amplified MYCN (MYCN transcriptionally activates the TERT
gene) or TERT rearrangement in neuroblastoma1,6. Activation of
alternative lengthening of telomeres (ALT) presents an alternative
route of telomere maintenance, which is seen in a substantial
proportion of neuroblastoma tumors1,6–8. Mutations in the
chromatin modifier alpha thalassemia/mental retardation syn-
drome X-linked (ATRX) are associated with elongated telomeres
and ALT in neuroblastoma7,8. Furthermore, deletions of ATRX
were associated with recurrent partial chromosomal losses in
neuroblastomas without amplified MYCN9. ATRX and its com-
plex partner death associated protein 6 (DAXX) incorporate
histone variant H3.3 at pericentric and telomeric repeat sequen-
ces10–12. ALT activity is strongly associated with somatic ATRX
mutations in different tumor entities13–16. Although loss of ATRX
alone does not induce ALT, ATRX acts as an ALT suppressor and
overexpression of ATRX in ATRX-mutant cells represses ALT
markers17,18. Interestingly, knockdown of DAXX abolishes the
ALT suppressive effect of ATRX overexpression in ATRX-mutant
cells highlighting the importance of both complex members17,18.
The clinical neuroblastoma risk stratification systems used by
most national and international consortia (Society For Pediatric
Oncology and Hematology-GPOH, International Society of Pae-
diatric Oncology Europe Neuroblastoma Group–SIOPEN, Chil-
dren’s Oncology Group-COG), as well as the International
Neuroblastoma Risk Group (INRG) staging system, categorizes
neuroblastomas mainly based on INSS stage, age, and MYCN
status into low risk, intermediate risk, and high risk19. Thus in
clinical practice, ALT-positive high-risk tumors are treated with
the same treatment protocol as MYCN-amplified and TERT-
rearranged tumors presuming similar biological features as these
telomerase-activated tumors1.
Focused studies on ALT in neuroblastoma are rare and pre-
vious observations were mostly based on genetic sequencing
studies and ATRX mutation status as ALT marker6–8. Here, we
aim to deepen the knowledge about the biology and clinical
features of ALT-positive neuroblastomas by enriching ALT
tumors in the study cohort independent of ATRX mutation sta-
tus. Using a multi-omics profiling approach of ALT-positive
neuroblastomas, we provide evidence that this subgroup is
clinically and molecularly distinct. Clinically, ALT is associated
with a protracted course of disease and poor outcome. Molecu-
larly, ALT-positive tumors feature mutated ATRX and/or reduced
protein abundance, heterochromatic telomeric chromatin, a slow
proliferative capacity, and frequent neo-telomere formation.
Results
Enrichment of ALT in relapsed disease. Using the presence of
circular partially single stranded extrachromosomal telomeric
repeat sequences (C-Circles) as ALT marker20, 9.2% of the neu-
roblastomas in a screening cohort of 720 tumors were classified as
ALT-positive. C-Circle screening was further extended to a
relapse cohort of tumors analyzed in the INFORM registry21
(n= 40). Importantly, 47.5% of the INFORM tumors were ALT-
activated, indicating a strong enrichment of this molecular sub-
group in relapsed cases (Fig. 1a, Tables 1–2). Clinically, ALT was
significantly associated with INSS stage 4, high-risk disease, and
an older age at diagnosis. However, about one third of the ALT-
positive neuroblastomas had localized disease and were stratified
at diagnosis as low or intermediate risk using a standard risk
classification system. In the screening cohort, none of the 83
tested 4 S stage tumors, a clinically recognizable subtype asso-
ciated with spontaneous regression seen in infants below one year
of age, were ALT-activated. Amplified MYCN and C-Circle pre-
sence were mutually exclusive in the screening cohort, but not in
the INFORM cohort (Tables 1–2, Supplementary Data 1–2).
Association of ALT with protracted clinical disease course and
poor outcome. Subsequently, neuroblastomas enriched for ALT
were characterized using a multi-omics approach including high
coverage whole genome sequencing (n= 165), RNA-sequencing
(n= 144), whole proteome analysis (n= 34), and ChIP-
sequencing (n= 27) (Fig. 1b, Supplementary Data 3, Methods)
forming the discovery cohort. ALT tumors had a significantly
higher telomere content (Fig. 2a). Telomere content and C-Circle
intensity was comparable between ALT-positive tumors of the
discovery and INFORM cohort (Supplementary Figs. 1–2).
Overall, telomere content was positively correlated with C-Circle
intensity (r= 0.76, P < 2.2e−16, Spearman, Supplementary
Fig. 1c). Minimal to no TERT mRNA expression was observed for
ALT-positive neuroblastomas (Fig. 2b), resulting from epigenetic
silencing of the TERT locus by H3K27me3 (Supplementary
Fig. 3a). In accordance with low TERT mRNA expression, ALT-
positive tumors exhibited low telomerase activity (Supplementary
Fig. 3b). Moreover, ALT was associated with increased expression
of the polyadenylated telomeric long noncoding RNA TERRA
(Fig. 2c, Supplementary Fig. 3c). Patients with ALT-positive
tumors had a similar poor event-free survival compared to
patients with MYCN-amplified tumors. Although the overall
survival time of patients with ALT-positive tumors was sig-
nificantly longer, they had a dismal outcome in the long per-
spective (Fig. 2d). No difference in event-free or overall survival
was observed between patients with ALT-positive tumors strati-
fied into high-risk and those predicted as low/intermediate risk
(Fig. 2e), indicating that the current risk stratification is under-
estimating the poor prognosis of ALT-positive tumors. ALT-
positive neuroblastomas with a higher telomere content had a
significantly shorter event-free survival as compared to ALT-
positive tumors with relatively lower telomere content (Supple-
mentary Fig. 3d). There was no clear trend in telomere content
gain or loss between matching primary/relapse samples of the
INFORM cohort (Supplementary Fig. 4). For 3 of 7 ALT-positive
relapse tumors with a matching primary, ALT activity was only
observed in the relapse tumor. Two of these cases were MYCN
amplified in the primary disease period and heterogeneous ALT/
MNA in the relapse. Heterogeneity could be confirmed by FISH
analysis (MYCN and telomere probe) of one relapsed tumor
(Supplementary Fig. 5a). For the other heterogeneous relapse
tumor, we found evidence of an ALT-positive subclone in FISH
analysis of the primary tumor (Supplementary Fig. 5b). Note-
worthy, the discovery cohort also contains three heterogeneous
ALT/MNA cases, which are MYCN amplified and have a very
high telomere content, but were otherwise C-Circle negative
(Fig. 2a, Supplementary Figs. 1a and 5c).
ATRX mutations in 55% of ALT-positive neuroblastomas. The
mutational landscape of ALT-positive neuroblastomas in the
discovery cohort was very diverse with only few recurrent genetic
events (Fig. 3a, Supplementary Fig. 6). ALT activation was
mutually exclusive to TERT rearrangements (Fig. 3a). Loss-of-
function mutations of ATRX were the most frequent events
associated with ALT, but were only observed in 55% of ALT-
positive tumors (Fig. 3a). ATRX mutations were mainly large
deletions and single nucleotide variants (Fig. 3a–b, Supplemen-
tary Data 3–4). However, three patients had large intragenic
ATRX duplications (Fig. 3a–b, Supplementary Data 3–4). Patient
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survival was not significantly different between ATRX-mutated
and ATRX wild-type ALT-positive cases (Fig. 3c). Mutations in
the ATRX complex members DAXX and H3F3A were extremely
rare (Fig. 3a). Only one ATRX wild-type tumor exhibited a large
inversion event affecting DAXX, associated with low DAXX
mRNA expression (66.46 TPM; range discovery cohort 50-330
TPM). Another tumor had an A92S H3F3A mutation in addition
to mutated ATRX. Somatic mutations in TP53 pathway genes
(TP53, CREBBP, ATM, ATR, CDKN2A, and MDM2) were sig-
nificantly enriched (P= 0.01) in ALT-positive tumors. ALT-
positive tumors had the highest prevalence of CDK4 amplifica-
tions (3/4) (Fig. 3a), associated with increased CDK4 mRNA
expression (Supplementary Fig. 7a), and showed higher CCND1
mRNA expression as compared to telomerase-activated cases
(Supplementary Fig. 7b). Overall, many tumors had mutations in
one or another gene associated with telomere maintenance
according to the TelNet database22 (Fig. 3a, Supplementary
Figs. 6 and 7c). Copy number loss of POLD3 and ATM was
frequently observed in ALT-positive tumors (Supplementary
Fig. 7c). However, both POLD3 and ATM are located on chr11q
and loss of these genes was associated with loss of chr11q, which
is frequently observed in ALT-positive (Supplementary Fig. 8)
and other non-MYCN-amplified neuroblastomas23,24. Synaptic
nuclear envelope protein 1 (SYNE1) was exclusively mutated in 7
of 60 ALT tumors (11.7%) (Fig. 3a, Supplementary Figs. 6, 9a).
Furthermore, deletions in receptor-type tyrosine-protein phos-
phatase delta (PTPRD) were enriched in ALT-positive tumors
(P= 2.46e-05; Fig. 3a, Supplementary Fig. 6). Structural varia-
tions affecting PTPRD were reported in neuroblastoma cohorts
and low PTPRD expression was correlated with a poor
prognosis25,26. However, structural variations of PTPRD were not
correlated with reduced PTPRD mRNA expression in our dis-
covery cohort (Supplementary Fig. 9b). Noteworthy, both genes
are very large and thus the high mutation frequency in ALT
neuroblastomas could also reflect the general increased muta-
tional load found in older patients or a general increase in
genomic instability (Supplementary Fig. 9c–e). The mutational
landscape of relapsed neuroblastomas in the INFORM cohort was
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Fig. 1 C-Circle screening of neuroblastomas. a ALT frequency detected using C-Circle presence as a marker in the screening cohort (n= 720, left) and
INFORM cohort (n= 40, right). Top pies illustrate the composition of the cohorts concerning INSS tumor stage. b Schematic overview of the analyzed
patient cohorts used for C-Circle screening and high-throughput analysis using whole genome sequencing (WGS), RNA-sequencing, whole proteome
analysis, and ChIP-sequencing. Sample numbers are given in brackets. Number of C-Circle positive (CC+) and C-Circle negative (CC-) patients in the sub-
cohorts are indicated.
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comparable to the discovery cohort (Supplementary Fig. 10a,
Supplementary Data 2, 3). In one matched primary relapse pair,
an ATRX duplication event was retained in the relapse, further
indicating that duplications can lead to nonfunctional ATRX
(Supplementary Fig. 4). Notably, canonical activating RAS path-
way mutations (HRAS, NRAS, KRAS, BRAF, RAF1, CDK4,
CCND1, NF1) were significantly more frequent in relapsed ALT-
positive neuroblastomas in the INFORM cohort compared to the
discovery cohort (P= 0.0013, Supplementary Fig. 10, Fig. 3a),
supporting a specific impact of RAS pathway mutations in
relapsed ALT-positive tumors.
Low ATRX protein abundance in ALT tumors. Using a mass
spectrometry based whole proteome approach (n= 34) quanti-
fying on average 6891 proteins per tumor, we found 470 proteins
significantly different in ALT-positive tumors compared to the
other subgroups (nominal P ≤ 0.01; fold change ≥2; Fig. 4a,
Supplementary Data 5). Enrichment analysis of significantly dif-
ferent mRNAs and proteins for each subgroup in turn highlighted
both the overall agreement of transcriptomics and proteomics as
well as the distinct effects only significantly present in one or the
other omics-level (Fig. 4b, Supplementary Fig. 11a, Supplemen-
tary Data 6). The Ras family proteins HRAS and NRAS, com-
prised in the term “prenylation”, were significantly upregulated in
ALT-positive neuroblastomas (Fig. 4b, Supplementary Data 6).
Among the top upregulated proteins in ALT-positive tumors
were the cancer testis antigens P antigen family member 5
(PAGE5) and melanoma associated antigen 4 (MAGEA4), which
may serve as potential targets for immunotherapies (Fig. 4a).
Many pathways associated with proliferation were significantly
downregulated on protein level in ALT-positive tumors com-
pared to the telomerase-activated tumors including “DNA repli-
cation” and “chromosome”. Notably, the classical proliferation
marker MKI6727, comprised in the term “chromosome”, was one
of the top significantly downregulated proteins in ALT-positive
Table 1 Clinical features of C-Circle positive tumors in the screening cohort (n= 720)a.
Total cohort C-Circle positive C-Circle negative P valueg
No.f %f No. f %f No.f %f
Total 720 66 9.2% 654 90.8%
Stage 1-3b 416 57.8% 25 37.9% 391 59.8% 1.948E-06
Stage 4b 221 30.7% 41 62.1% 180 27.5%
Stage 4Sb 83 11.5% 0 0.0% 83 12.7% 0.000367
LR/IRc 449 65.9% 24 36.9% 425 69.0% 6.944E-07
HRc 232 34.1% 41 63.1% 191 31.0%
Male 397 55.1% 39 59.1% 358 54.7% 0.519
Female 323 44.9% 27 40.9% 296 45.3%
Aged (mean in days) 871 2872 669 <2E-16
MYCN ampe 114 16.2% 0 0.0% 114 17.9% 5.883E-06
MYCN normale 588 83.8% 66 100.0% 522 82.1%
Ganglioneuroma 11 1.5% 0 0.0% 11 1.7% 0.6115
an refers to the number of tumors.
bTumor staging was done according to the INSS criteria.
cRisk stratification was based on the German Neuroblastoma Study NB2004. Risk stratification was not available for 39 tumors.
dAge at diagnosis.
eMYCN status refers to MYCN status at diagnosis, which is either amplified (amp, ≥8 copies) or normal. MYCN status was not available or inconclusive for 18 tumors.
fAll values are given in absolute number of tumors (No.) and relative (%) to the total number of tumors in each group (total cohort, C-Circle positive, C-Circle negative).
gP values were calculated using Fisher tests and two-sided Wilcoxon rank sum test (age).
Table 2 Clinical features of C-Circle positive tumors in the INFORM cohort (n= 40)a.
Total cohort C-Circle positive C-Circle negative P valueg
No.f %f No.f %f No.f %f
Total 40 19 47.5% 21 52.5%
Stage 1-3b 4 10.0% 4 21.1% 0 0.0% 0.041
Stage 4b 34 85.0% 14 73.7% 20 95.2%
Stage 4Sb 2 5.0% 1 5.3% 1 4.8% 1.000
LR/IRc 7 17.5% 5 26.3% 2 9.5% 0.226
HRc 33 82.5% 14 73.7% 19 90.5%
Male 32 80.0% 13 68.4% 19 90.5% 0.120
Female 8 20.0% 6 31.6% 2 9.5%
Aged (mean in days) 1645 2243 1104 0.003
MYCN ampe 11 27.5% 2 10.5% 9 42.9% 0.029
MYCN normale 28 70.0% 17 89.5% 10 47.6%
an refers to the number of tumors.
bTumor staging was done according to the INSS criteria.
cRisk stratification was based on the German Neuroblastoma Study NB2004.
dAge at diagnosis.
eMYCN status refers to MYCN status at diagnosis, which is either amplified (amp, ≥8 copies) or normal. MYCN status was inconclusive for one tumor at diagnosis.
fAll values are given in absolute number of tumors (No.) and relative (%) to the total number of tumors in each group (total cohort, C-Circle positive, C-Circle negative).
gP values were calculated using Fisher tests and two-sided Wilcoxon rank sum test (age).
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neuroblastomas (Fig. 4a–b, Supplementary Fig. 11b). The term
DNA replication includes among others the proteins PCNA,
MCM2, MCM3, MCM4, MCM5, and MCM7, which are also
indicative of the proliferative capacity of a cell28. Furthermore,
the term “bromodomain” was significantly reduced in ALT-
positive tumors, while strongly upregulated in MNA tumors.
Amplified MYCN is known to be associated with increased
occupancy of active promoter regions and enhancer invasion by
MYCN and bromodomain proteins, leading to an increased
transcriptional activity of many proliferation associated genes and
downregulation of differentiation genes29. Moreover, ALT-
positive tumors exhibit a significantly lower fraction of cycling
cells compared to MYCN-amplified tumors (Supplementary
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cycle analysis support a low proliferative capacity of ALT-positive
neuroblastomas. 96 of the 470 significantly different proteins were
annotated in the TelNet database to be associated with telomere
maintenance22 (Supplementary Data 5) (P= 0.03). The sig-
nificantly downregulated proteins in ALT-positive neuro-
blastomas comprised ATRX, PCNA, EXO1, GNL3, KDM1A,
RIF1, SCG2, TFAP2B, and GNL3L, all functionally linked to
telomere maintenance22. Helicases and chromatin regulators,
including ATRX, were less abundant at protein level in the ALT
subgroup, but not at mRNA level (Fig. 4b). Importantly, ATRX
itself was among the top candidates to exhibit lower protein
abundance in ALT-positive tumors (Fig. 4a). Intriguingly, the
reduced ATRX protein levels were independent of ATRX mRNA
levels and mutation status (Fig. 5a). ATRX was among the most
strongly downregulated proteins while the ATRX mRNA changes
very little (Supplementary Fig. 11d), indicating that reduced
ATRX protein abundance is a characteristic proteomic feature of
all ALT-positive tumors (ATRX wild-type and mutated) that
cannot be observed at the mRNA level. Analysis of exon-specific
ATRX mRNA levels revealed that only the exons affected by
deletion have reduced expression in the ATRX-deleted cases
(Supplementary Fig. 12a). In summary, reduced ATRX protein
level is a biomarker for ALT-positive neuroblastomas that is
independent of mRNA levels and ATRX mutation. The decreased
ATRX protein levels despite unchanged mRNA abundance could
be due to reduced translation and/or increased degradation of
ATRX in ALT-positive tumors. For example, it has been shown
that unassembled subunits of multiprotein complexes (so-called
orphans) are often degraded30. Downregulating one subunit can
therefore induce degradation of other subunits, which partially
explains divergence of protein- and mRNA-level changes in many
biological contexts31,32. We therefore took a closer look at the
ATRX binding partner DAXX. Interestingly, DAXX protein levels
were specifically reduced in ALT-positive ATRX wild-type tumors
(Fig. 5b). To investigate if reduced DAXX levels could explain
ATRX downregulation at the protein level, we knocked-down
DAXX in the ALT-negative neuroblastoma cell line NBL-S and
observed that ATRX protein levels were indeed reduced after 96 h
(Fig. 5c–d). Hence, the reduced ATRX protein levels in ATRX
wild-type ALT positive tumors might result from downregulation
of the DAXX protein. However, since DAXX mRNA levels do not
differ significantly between tumors (Fig. 5b) and no recurrent
mutation patterns in DAXX or ATRX/DAXX interacting proteins
could be identified in ALT-positive ATRX wild-type tumors
(Supplementary Figs. 12b, 13), the question what causes the
downregulation of DAXX is still open. Hence, the mechanistic
details behind ATRX/DAXX complex reduction remain to be
uncovered.
Heterochromatic telomeric chromatin in ALT neuroblastomas.
Many contradictory findings were reported on the telomeric
chromatin landscape of ALT-positive cells33–35, but data on
primary tumor samples was yet missing. Here, ALT-positive
neuroblastoma tumors were found to be enriched for H3K9me3
at the telomeres (Fig. 6a). Overall levels of H3K9me3 at the tel-
omeres of ALT-positive tumors were comparable to the
H3K9me3 levels at SatII and SatIII alpha-satellite sequences
(Supplementary Fig. 14a–b), which are known to be enriched for
H3K9me335,36. In line with a heterochromatic enrichment, pro-
tein expression of the demethylase KDM1A responsible for
removing methyl groups from H3K9me337 was significantly
lower in ALT-positive neuroblastomas compared to TERT-acti-
vated tumors (Fig. 6b). SETDB1 protein activity is required for
H3K9me3 deposition at the telomeres, while the histone
methyltransferases SUV39H1 and SUV39H2 catalyze H3K9 tri-
methylation at heterochromatic sites38–40. Neither expression of
SETDB1 nor SUV39H1/SUV39H2 could be associated with the
increased telomeric H3K9me3 in ALT-positive neuroblastomas
(Fig. 6c–d). H3K27ac at the telomeres was lower in ALT-positive
tumors (Fig. 6a). However, this difference was not telomere
specific and similarly observed at SatII and SatIII sequences
indicating a general difference in H3K27ac (Supplementary
Fig. 14c). Furthermore, ALT-positive tumors displayed reduced
telomeric H3K27me3 (Fig. 6a, Supplementary Fig. 14d) and low
protein and mRNA expression of the PRC2 component EZH2,
responsible for H3K27me3 deposition (Fig. 6e). Low H3K36me3
was observed at the telomeres and satellite sequences of both
ALT-positive and ALT-negative neuroblastomas (Fig. 6a, Sup-
plementary Fig. 14e). Together, this indicates epigenetic dysre-
gulation of repressive marks at the telomeres in ALT-positive
tumors with excess of H3K9me3 and reduction of H3K27me3.
Increased frequency of telomeric repeat loci in ALT tumors.
ALT-positive neuroblastomas exhibited an increased frequency of
telomeric repeat loci compared to the other groups (Fig. 7a), with
ALT-positive tumors displaying up to 19 such events per tumor.
The telomeric repeat loci frequency was significantly higher in
ATRX-mutated than ATRX wild-type ALT tumors. Telomeric
repeat loci are characterized by a chromosomal junction site and
the presence of telomeric repeat sequences either upstream or
downstream of this junction site (one-sided) (Fig. 7b). In rare
cases, two telomeric repeat loci in close proximity (10 kb) with
opposite orientation can form a two-sided event (Supplementary
Fig. 15a). In our discovery cohort, only five such two-sided events
were observed (Supplementary Fig. 15b). Two-sided events can
result either from two separate events in close proximity or from
telomere sequences that are spanning the region between the two
junction sites forming a true insertion. Evidence for a true
insertion, meaning that mates of a read pair matched to both
sides of the insertion could only be identified for two of these
events (Supplementary Table 1). The presence of more than three
telomeric repeat loci in a tumor was found to be associated with a
significantly reduced overall survival in ALT-positive neuro-
blastomas (Fig. 7c). Hotspot regions for recurrent telomeric
Fig. 2 Characteristics and survival of ALT-positive neuroblastomas. a Relative telomere content (tumor/control) of neuroblastoma tumors in the
discovery cohort grouped according to the genetic evidence of an active telomere maintenance mechanism (see methods for details): ALT activation (ALT,
red), telomerase activation by amplified MYCN (MNA, yellow), structural variation affecting TERT or TERT promoter mutation (TERT, blue), and
patients having no genetic evidence of an activated telomere maintenance mechanism (OTHER, gray). b TERT mRNA expression in different subgroups.
c Expression of the telomeric repeat-containing RNA TERRA in the different subgroups. a–c Boxplots indicate the median value (middle line), the 25th and
75th percentiles (box). The upper/lower whisker spans from the hinge to the largest/smallest value (values expanding a distance of 1.5 x inter quartile
range are not considered). Dots represent individual tumors. P values were calculated with two-sided Wilcoxon rank sum tests. d Event-free and overall
survival probability compared between ALT-positive (n= 60) and MYCN-amplified (MNA, n= 34) neuroblastomas. e Event-free and overall survival
probability of patients with ALT-positive tumors classified as low or intermediate risk (LR/IR, n= 20) compared to patients with ALT-positive tumors
classified as high-risk (HR, n= 39) using the NB2004 risk stratification. d–e P values were calculated using log rank tests. a–e n describes the number of
analyzed tumors.
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repeat loci were found on chromosomes 1q42.2, 18q23, and
19q13.43 (Fig. 7d). The increased occurrence of telomeric repeat
loci in ALT-positive neuroblastomas and their enrichment on
1q42.2 was confirmed in the INFORM dataset (Supplementary
Fig. 15c). 80.3% (212/264) of all t-type (TTAGGG) containing
telomeric repeat loci showed at least 1 bp microhomology to the
canonical telomeric repeat sequence, which is more than one
would expect by chance. This enhanced microhomology at the
junction sites of telomeric repeat loci indicates that telomeric
sequences were added via a microhomology-dependent
mechanism (Supplementary Fig. 15d-f). In general, 55.3% of all
telomeric repeat loci were associated with a chromosomal copy
b
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number loss of the neighboring segment (Supplementary
Fig. 15g). A smaller fraction of loci (4.9%) was associated with a
copy number gain. However, 30.7% of the telomeric repeat loci
were copy number neutral. Some of these copy number neutral
events were associated with one or more structural variations, but
for 77.2% of the copy number neutral telomeric repeat loci no
other event could be detected (Supplementary Fig. 15g).
1q42.2 telomere repeat locus coincides with 1q42-1qter dele-
tions. Telomeric repeat loci contributing to the hotspot on
chr1q42.2 (230.370 mb – 231.433 mb, Fig. 7e) frequently coin-
cided with loss of the adjacent segment of chr1q (Fig. 7f).
Telomeric repeat loci at 1q42.2 showed a high degree of
microhomology to the telomeric TTAGGG repeats (Supple-
mentary Figs. 15e, 16a). Loss of chromosome 1q42.2-1qter was
also observed in some tumors without the occurrence of telo-
meric repeats at this site. However, 1q42.2-1qter deletions were
exclusively seen in ALT-positive tumors, most of which had an
ATRX mutation (Supplementary Figs. 16b, 8). RNA expression
of most genes in the deleted 1q region was lower in 1q42.2-1qter
deleted compared to non-deleted tumors (Fig. 7g). Among the
significantly reduced genes in 1q42.2-1qter deleted tumors were
the genes ARID4B, EXO1, FH, CNST, ADSS, HNRNPU, and
RYR2, which are known to be associated with telomere main-
tenance and biology22. Of note, expression of the 5′−3′ exo-
nuclease, EXO1, located on chromosome 1q43 and involved in
DNA double strand break repair41,42, telomere replication, and
t-loop formation43, was not only reduced in 1q42.2-deleted
tumors but generally reduced in ALT-positive neuroblastomas
(Supplementary Fig. 16c).
Discussion
In summary, this in-depth analysis revealed that ALT-positive
neuroblastomas are biologically and clinically distinct from
tumors with telomerase activation.
ALT in neuroblastoma was associated with characteristic ALT
features, including high telomere content, low TERT expression,
and increased TERRA expression, which is in line with previous
findings on ALT-positive tumors44,45. ATRX mutations were
identified in 55% of the ALT-positive neuroblastomas. In line
with this observation, an ATRX mutation frequency of 60% was
reported in a parallel study46. The most frequent type of ATRX
mutations were large deletions. However, we could also identify
focal intragenic ATRX duplication events. Focal duplication of
ATRX was also observed in a matching primary/relapse pair
indicating that these events are leading to loss of ATRX. Similar
events resulted in loss of ATRX function in patients with the
genetic disorder alpha thalassemia X-linked intellectual disability
syndrome (ATRX-syndrome)47,48 further supporting a loss of
ATRX function by partial duplications.
Integrating proteomic profiling revealed reduced ATRX/DAXX
protein complex abundance as a recurrent event in ALT-positive
neuroblastoma, which could often not be explained by mutations in
these genes. The observation that all five ALT-positive tumors with
wild-type ATRX depicted reduced DAXX protein levels is intri-
guing. It is tempting to speculate that the ALT phenotype always
results from loss of the ATRX/DAXX complex activity, which is
caused either by ATRX mutations or by reduced ATRX/DAXX
protein levels. Future studies will show if this is indeed the case in
neuroblastoma and/or possibly other ALT-positive cancers.
Nevertheless, we could identify a subgroup of ALT-positive
neuroblastomas with wild-type ATRX, but low ATRX protein
abundance. Reduced ATRX protein levels in ALT ATRX wild-
type neuroblastoma could be explained by the reduced DAXX
protein levels, which we specifically observed in this subgroup of
tumors. In this scenario, reduced DAXX protein levels impair
assembly of the ATRX/DAXX complex, which then causes
degradation of orphan ATRX protein molecules. Consistent with
this idea, we observed that knocking down DAXX reduced ATRX
protein levels in neuroblastoma cells. However, the cause of
reduced DAXX protein levels is not yet clear, especially since
mRNA levels do not change significantly. Reduced DAXX protein
levels in ALT-positive tumors may result from posttranscriptional
events. It is known that DAXX is regulated via various post-
translational modifications including phosphorylation, SUMOy-
lation, and ubiquitination49. Irrespective of the mechanistic
details involved, our study highlights that proteomic data is closer
to phenotypes than transcriptomic data, which is especially
valuable in a clinical context32.
A recent report stated that ATRX mutation and amplified
MYCN are mutually exclusive50. C-Circle screening of a cohort of
720 neuroblastomas also found a mutual exclusivity of C-Circle
presence and amplified MYCN. However, in the INFORM cohort
we identified two cases with amplified MYCN and a positive C-
Circle signal. Additionally, in our discovery cohort we classified
three cases as ALT/MNA heterogeneous. These cases were
negative in the C-Circle assay, but exhibited a very high telomere
content. FISH analysis of some of these cases could also confirm
that amplified MYCN and ultra-bright telomere spots are present
in the same tumor (Supplementary Fig. 5). No ATRX mutations
were detected in the MNA/ALT heterogeneous tumors (for
NBI26 only lcWGS and WES data was available). Taken together,
heterogeneous tumors with amplified MYCN and presence of
ALT markers seem to occur, but are very rare. Further analysis
and larger sets of these cases would be necessary to draw
meaningful conclusions on the clonality of these events and the
activity of the respective telomere maintenance mechanism.
ChIP-sequencing analysis of ALT-positive neuroblastoma
tumors showed that telomeres as well as SatII and SatIII
sequences show lower H3K27ac compared to ALT-negative
tumors. Furthermore, proteins comprised in the term “bromo-
domain”, including EP300 responsible for H3K27ac, were
reduced in ALT tumors and enhanced in telomerase-activated
tumors. Moreover, the telomeres of ALT-positive neuro-
blastoma tumors were enriched for H3K9me3. These observa-
tions confirm the results of a previous study on cell lines35 that
only the telomeres of ALT-positive tumors are enriched for
H3K9me3. In addition, we observed low H3K27me3 at the tel-
omeres of ALT cases, which goes in line with a significantly
Fig. 3 Mutational landscape of ALT-positive neuroblastomas. a Somatic alterations in the discovery cohort. Samples ordered based on relative telomere
content. Exonic single nucleotide variations (SNVs), exonic small insertions and deletions (INDELs) and structural variations in exonic and intronic regions
(SVs) in selected ALT-associated genes, genes associated with telomere biology according to the TelNet database22 [https://malone2.bioquant.uni-
heidelberg.de/fmi/webd/TelNet] and TP53 pathway genes are illustrated. Telomere maintenance features, clinical features, chromosomal aberrations, and
ALK/RAS pathway mutations (HRAS, NRAS, KRAS, BRAF, NF1 or ALK) are given in the top panel. b Exact genetic location of mutations affecting the ATRX
gene. Bars represent structural variations (deletion, duplication) and small deletions, while SNVs are illustrated as lollipops and colored by the SNV type.
c Event-free and overall survival rate of patients with an ATRX-mutated ALT-positive neuroblastoma (n= 33) compared to patients with an ATRX wild-type
ALT-positive neuroblastoma (n= 27). P values were calculated using a log rank test. n describes the number of analyzed tumors.
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Fig. 4 Proteomic analysis of ALT-positive neuroblastomas. a Label free quantification (LFQ) analysis comparing ALT tumors with MNA and TERT tumors
as well as tumors without a genetic telomere maintenance mechanism (OTHER). P values were calculated using a two-sided Student’s t-test. Colors
indicate P value and fold change categories as well as the association to telomere biology based on the TelNet database22 [https://malone2.bioquant.uni-
heidelberg.de/fmi/webd/TelNet]. b Differences between neuroblastoma subtypes (ALT, TERT, MNA, OTHER). UniProt keywords ([https://www.uniprot.
org/keywords/]; retrieved on 2016-11-02) with significant enrichments (BH adjusted P < 0.000005, at least 2.5-fold enriched, at least 3 protein/mRNAs
per keyword) in at least one group with significantly more or less abundant mRNA or proteins comparing each group to all other samples in turn (BH
adjusted P < 0.05, * marks significant enrichment). Positive and negative sqrt enrichment values for enrichments in more and less abundant mRNA or
protein, respectively. Enrichment P values were calculated by hypergeometric test and multiple-testing adjusted by Benjamini–Hochberg method. Exact
P values and individual proteins contributing to Uniprot keywords are given in Supplementary Data 6.
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lower protein and mRNA expression of EZH2 in ALT neuro-
blastomas compared to telomerase-activated tumors.
ALT-positive neuroblastoma tumors exhibited a high rate of
telomeric repeat loci. Since telomeric repeat loci were characterized
by telomeric repeat sequences either upstream or downstream of a
non-telomeric junction site, these events cannot have occurred from
breakage of interstitial telomeric sequences (ITS). However, telo-
meric repeat loci frequently overlapped with breakpoints of copy
number changes or structural variations. Because terminal chro-
mosomal breaks are in need of telomeric repeats to protect the
newly formed ends from degradation51–53, we propose that ALT-
positive tumors are capable of adding telomeric repeat sequences to
open ends of chromosomal breaks forming neo-telomeres (Fig. 8a).
The high degree of microhomology to the telomeric repeat
sequence at the junction sites indicates that telomeric repeats are
added via a microhomology-dependent process like
microhomology-mediated end-joining or non-homologous end-
joining54. Further, we propose that the presence of microhomology
at an open chromosomal break determines if telomeric sequences
can be added to this site. Chromosomal loss of certain fragments
might present a selection advantage leading to a selection of cells
harboring the neo-telomere. We also identified a subset of copy
number neutral telomeric repeat loci with no associated structural
variation. This might be due to the fact that these events are sub-
clonal and were thus not detected by the CNV/SV calling algorithm.
Moreover, the detection limit of the used copy number algorithm is
50 kb and thus smaller copy number changes cannot be detected.
Two-sided events, defined as two telomeric repeat loci in a 10 kb
window with opposite orientation of the telomeric repeats, were
very rare. These events may represent insertions of telomeric repeat
sequences similar to previously described events55. Only two of five
two-sided events exhibited evidence of a true insertion by mates of a
read pair mapping to both sides of the insertion. However, for large
insertions the used short read sequencing prevents the detection of
supporting reads. Alternatively, two-sided events may result from
neo-telomere formation on both sides of a breakpoint (Fig. 8b). A
recurrent hotspot for telomeric repeat loci was identified on
chr1q42, which was associated with 1q42.2-1qter loss forming a
neo-telomere on chr1q42.2. Telomeric repeat loci were also asso-
ciated with ALT and overlapped with chromosomal breakpoints in
a pan-cancer cohort, but no enrichment was seen for telomeric
repeat loci on 1q42.245, indicating that neo-telomere formation on
chromosome 1q42.2 is neuroblastoma-specific. 1q42.2-1qter dele-







































































































































































































































































































Fig. 5 ATRX/DAXX complex abundance. a ATRX protein and ATRXmRNA expression in ALT ATRX-mutated (dark pink) and wild-type (light pink) tumors
compared to TERT (blue), MNA (yellow), and OTHER (gray). b Boxplots of DAXX protein and DAXX mRNA expression in ALT ATRX-mutated (dark pink)
and wild-type (light pink) tumors compared to TERT (blue), MNA (yellow), and OTHER (gray). a, b Boxplots indicate the median value (middle line) and
the 25th and 75th percentiles (box). The upper/lower whisker spans from the hinge to the largest/smallest value (values expanding a distance of 1.5 x inter
quartile range are not considered). Dots represent individual tumors. P values in boxplots were calculated with two-sided Wilcoxon rank sum tests.
n describes the number of analyzed tumors. c, d ATRX protein expression in NBL-S cells (with moderate MYCN expression) after 96 h treatment with
siRNAs against DAXX (black). ATRX siRNAs as well as two negative control siRNAs were used as controls (gray). Exemplary western blot (c) and
quantification of three biological replicates (d) is shown. P values calculated using a two-sided Student’s t-test. Horizontal line shows median value.
Dots represent biological replicates. Uncut images of all biological replicates are shown in the source data file.
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of the deletion. Furthermore, chr1q42.2-1qter deletions were asso-
ciated with reduced expression of candidate genes involved in tel-
omere biology, including EXO1. Interestingly, EXO1 expression is
not only reduced in ALT-positive tumors with 1q42.2-1qter dele-
tions, but in ALT tumors in general. This indicates a potential role
of EXO1 as an ALT suppressor that may be silenced by loss of
1q42.2 or other means.
ALT activity was associated with unfavorable outcome and a
protracted clinical course of disease, which further substantiates
previous observations56. Furthermore, ALT was enriched in a
population-based clinical sequencing study cohort for relapsed
neuroblastomas. Multiple factors may contribute to this
enrichment in the INFORM cohort. The INFORM inclusion
criteria might contribute to an underrepresentation of the most
aggressive neuroblastomas, which are most likely MYCN-
amplified or TERT-rearranged, since patients are required to
have sufficient general condition and a life expectancy of at
least three months to be included in the registry trial. Fur-
thermore, we could show risk underestimation of a substantial
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Fig. 6 Telomeric chromatin state of ALT-positive neuroblastomas. a Telomere repeats in ChIP of H3K9me3 (n= 26), H3K27ac (n= 25), H3K27me3
(n= 25) and H3K36me3 (n= 27) relative to telomere repeats in input of ALT-positive and ALT-negative tumors. b–e Protein and mRNA expression
of KDM1A (b), SETDB1 (c), SUV39H1/H2 (d, only RNA), and EZH2 (e) in ALT tumors compared to tumors form the other groups (TERT, MNA, OTHER).
a–e Colors indicate subgrouping based on presence and type of telomere maintenance mechanism (see legend). Boxplots indicate the median value
(middle line) and the 25th and 75th percentiles (box). The upper/lower whisker spans from the hinge to the largest/smallest value (values expanding a
distance of 1.5 x inter quartile range are not considered). Dots represent individual tumors. P values were calculated using a two-sided Wilcoxon rank sum
test. n describes the number of analyzed tumors.
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diagnosed as low or intermediate risk, but nevertheless had
poor outcome. The current standard treatment regimens tar-
geting strongly proliferating tumors are probably not suited to
treat slowly growing ALT tumors, which might lead to a
selection and enrichment of ALT-positive cases or subclones in
the relapse setting. Thus, ALT activation might present a
therapy resistance mechanism. Analysis of matching primary/
relapse pairs revealed a gain of ALT or outgrowth of an ALT-
positive subclone in the relapse tumor. Taken together, a
revised therapy concept based on a better molecular under-
standing of this subtype and considering ALT-specific vulner-
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Methods
Patient cohorts and tumor samples. We retrospectively analyzed cohorts of
primary and relapsed neuroblastoma tumors. ALT-activity was determined using
C-Circle assays for 720 neuroblastoma tumors (screening cohort, Supplementary
Data 1). High coverage whole genome sequencing (WGS) data was obtained for a
subset of 165 tumors (discovery cohort). RNA-sequencing (n= 144), whole
proteome analysis (n= 34), and ChIP-sequencing (n= 27) was done for subsets of
the discovery cohort. A summary of the clinical information and available data for
every patient in the discovery cohort is given in Supplementary Data 3. Patients
were enrolled in the neuroblastoma clinical trials (NB2004-HR/NCT03042429,
GPOH-NB2004/NCT00410631, GER-GPOH-NB97/NCT00017225, GER-NB95-S/
NCT00002803, GER-NB90/NCT00002802, NB2016-registry) of the Society for
Fig. 7 Telomeric repeat loci. a Telomeric repeat loci frequency in ATRX-mutated (dark pink) and ATRX wild-type (light pink) ALT-positive tumors
compared to TERT (blue), MNA (MNA), and tumors without genetic evidence of an activated telomere maintenance mechanism (OTHER, gray) in the
discovery cohort. Boxplots indicate the median value (middle line) and the 25th and 75th percentiles (box). The upper/lower whisker spans from the hinge
to the largest/smallest value (values expanding a distance of 1.5 x inter quartile range are not considered). Dots represent individual tumors. n describes
the number of analyzed tumors. P values were calculated with two-sided Wilcoxon rank sum tests. b Example of one telomeric repeat locus in tumor
NBD119. Dark blue color indicates sequencing coverage and light blue color illustrates clipped sequences. Reads are shown in medium gray and clipped
bases are color-coded. Non-telomeric ends of a discordant read pair are labeled in dark gray. c Overall survival probability of ALT-positive tumors harboring
more than three telomeric repeat loci compared to ALT-positive tumors with three or less than three events. P value calculated using a log rank test.
d Chromosomal location of telomeric repeat loci in the discovery cohort. e Exact genomic location of events contributing to the hotspot on chromosome
1q42.2 in the discovery and INFORM cohort and two ALT-positive cell lines. The 1q42.2 events of NBD158 and NBD137 ware added manually (see
Methods). f Chr1 copy number profiles of tumors with a telomeric repeat locus on chr1q42.2. Junction sites and orientation of telomeric repeats are
indicated in orange. Color-coding according to subgroup (# HET ALT/MNA). g Differential mRNA expression of genes located in the chr1q42.2-1qter
deleted region comparing 1q42-1qter deleted to non-deleted tumors. Genes are colored by their mean expression normalized by exonic length or by their
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Fig. 8 Model of neo-telomere formation. Graphical abstract illustrating the hypothesis of neo-telomere formation in ALT-positive neuroblastomas. a The
majority of telomeric repeat loci are one-sided. We hypothesize that ALT-positive cells are able to add telomeric sequences to open chromosomal breaks
to protect them from degradation. I Microhomology to TTAGGG favors the formation of a neo-telomere at the open chromosomal break. Loss of some
chromosomal regions might present a selection advantage for the cell and cells with a neo-telomere at the chromosomal breakpoint are selected.
II Without microhomology, structural rearrangements involving other chromosomal arms (light gray) can represent an alternative route of protecting
open chromosomal breaks. b Rare two-sided events can result from insertion of telomeric sequences I or from the formation of neo-telomeres on
both sides of the breakpoint II. Small circles represent C-Circles. Chromosomes are shown in gray and telomeric sequences in blue.
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Pediatric Oncology and Hematology (GPOH) between 1991 and 2018. All trials
were approved by the Ethics Committee of the Medical Faculty, University of
Cologne and collection and use of all tumor tissue material was approved. Tumors
of nine Austrian neuroblastoma patients were analyzed as part of the screening and
discovery cohort. Tumor and control DNA/RNA was provided by Prof. Dr. Peter
Ambros and Dr. Sabine Taschner-Mandl from the St. Anna Kinderkrebsforschung
at the Children’s Cancer Research Institute in Vienna, Austria. Austrian neuro-
blastoma patients were in part enrolled in the NB-A-8757 or the HR-NBL-1/
SIOPEN58 trial (NCT01704716, EudraCT number 2006-001489-17). The copy
number status of MYCN using FISH analysis was assessed as a routine diagnostic
marker in all neuroblastoma clinical trials. Survival data for German patients of the
discovery cohort was provided by Dr. Barbara Hero from the study office of the
Neuroblastoma trial in Cologne. Additionally, a relapsed neuroblastoma cohort of
patients enrolled in the registry trial INFORM21 was analyzed (n= 40). Whole
exome sequencing and low coverage whole genome sequencing was done as part of
the INFORM workflow21. For a subset of these (n= 31) high coverage whole
genome sequencing was done. A detailed overview of all clinical parameters and
available data of the INFORM cohort is given in Supplementary Data 2. All
patients or their legal guardian signed a written informed consent. Genomic DNA
was isolated from fresh frozen material using a phenol chloroform extraction and
control DNA was isolated from whole blood using the NucleoSpin Blood DNA
extraction kit (Macherey-Nagel).
C-Circle assay. C-Circle assays were performed based on a previously described
protocol20, which is briefly described in the following. 30 ng of genomic DNA were
used for every tumor sample. Prior to amplification, tumor DNA was digested with
RsaI (4U/ug) and HinfI (4U/ug) and RNAse (25 ng/μg) treated for 1 h at 37 °C.
0.2 mg/mL BSA, 0.1% Tween 20, 1 mM dATP, dGTP and dTTP, 2 x Φ29 buffer
and 7.5 U Φ29 polymerase was added to the pretreated DNA and rolling circle
amplification was done at 30 °C for 8 h, followed by an inactivation at 65 °C for
20 min. For every sample, a sample without polymerase was included as control
and on every blot the neuroblastoma cell lines CHLA-90 (ALT-positive) and SK-N-
BE2 (ALT-negative) were included as positive and negative assay controls. Tel-
oTTAGGG kit (Roche) was used for hybridization and development according to
the manufacturers’ instructions. All blots were quantified using the ImageJ gel
quantification tool (ImageJ version 1.51). A C-Circle positive signal was defined as
minimum 4-fold increase of the area under the curve relative to control without
polymerase. In addition, the signal intensity had to be at least 20% of the CHLA-90
positive control. C-Circle status was assessed by quantification and optical
inspection of all blots by two investigators.
Whole genome sequencing. High coverage whole genome sequencing libraries
were sequenced on the Illumina HiSeq 2000 (100 bp paired end) or on a patterned
flowcell v.2.5 (150 bp paired end) with coverage of 30–60x for the tumor and whole
blood control samples. Tumor samples exhibited a tumor cell content of ≥60%.
Sequencing libraries for the Illumina HiSeq 2000 platform were generated using the
NEB Next Ultra DNA kit (NEB) according to the manufacturers’ instructions.
Libraries for sequencing on the patterned flowcell v2.5 were generated using the
Truseq DNA Nano kit (Illumina) according to the manufacturers’ instructions.
Libraries were size selected using SPRI beads (Beckman Coulter Genomics). One
Touch Pipeline (OTP) service of the German Cancer Research Center (DKFZ)59
was used for alignment and variant calling. Whole genome sequencing data was
aligned to the 1000 Genomes project phase 3 assembly with decoy and PhiX
contigs reference genome using BWA-MEM version 0.7.8, 0.7.8-r2.08 or 0.7.15
with option -T 0. Sambamba version 0.6.5 was used for merging and duplication
marking and bam files were filtered using Samtools version 0.1.19. The SNV calling
workflow is available at [https://github.com/DKFZ-ODCF/SNVCallingWorkflow].
Copy number variations were assessed using ACEseq version 1.2.860, which was
additionally used to assess the quality of the sequencing data. The ACEseq
workflow is available at [https://github.com/DKFZ-ODCF/ACEseqWorkflow].
Genes were defined as amplified if the copy number was at least 8-fold higher than
the total copy number of the tumor sample. Any copy number losses that were not
homozygous deletions were defined as a deletion. Any loss of heterozygosity (LOH)
that was not also a deletion (e.g., copy-neutral LOH) was defined as LOH. Small
insertions and deletions were determined based on an OTP in-house workflow61,
which is available at [https://github.com/DKFZ-ODCF/IndelCallingWorkflow].
SOPHIA version 1.0.16 or 1.2.16 was used for detection of structural variants. SV
calling workflow is available at [https://github.com/DKFZ-ODCF/
SophiaWorkflow]. Structural variants affecting ATRX and TERT were determined
using SOPHIA in combination with a manual inspection in the Integrated
Genomics Viewer (IGV)62,63. TERT promoter mutations (C228T and C250T) were
specifically analyzed using less stringent criteria for mutation calling (mutated base
in at least two reads, mutation frequency ≥20%). Candidate genes associated with
telomere maintenance and biology were identified using the TelNet database22
[https://malone2.bioquant.uni-heidelberg.de/fmi/webd/TelNet]. Genes encoding
ATRX and DAXX interaction partners were extracted from the BioGRID database
[https://thebiogrid.org/].
Telomere length analysis. The telomere content was calculated using the software
tool TelomereHunter64 version 1.0.1. TelomereHunter v1.0.1 is available at
[https://www.dkfz.de/en/applied-bioinformatics/telomerehunter/telomerehunter.
html]. Telomeric reads containing six non-consecutive instances of the four most
common telomeric repeat types (TTAGGG, TCAGGG, TGAGGG, and TTGGGG)
were extracted. For the further analysis, only unmapped reads or reads with a very
low alignment confidence (mapping quality lower than 8) were used. Telomere
read count was normalized by all reads in the sample with a GC-content of 48–52%
and furthermore telomere content of tumor samples was normalized to the
matching blood control. For tumor samples without a matching control, the mean
telomere content of all controls sequenced with the same protocol in the same
sequencing center was used for normalization.
Subgrouping based on telomere maintenance mechanism (TMM group). All
tumors were categorized into four groups according to the genetic evidence of an
activated telomere maintenance mechanism (ALT, MNA, TERT) or the absence of
such a mechanism (OTHER). Tumors being either C-Circle positive or having a
log2 telomere content relative to the control sample >1 were classified as ALT.
Tumors with an amplified MYCN gene were considered to use telomerase acti-
vation by MYCN (MNA). The TERT group comprises tumors with a structural
variation affecting TERT or TERT promoter mutation. Tumors with a relative log2
telomere content above one and amplified MYCN were included in the hetero-
geneous group HET ALT/MNA despite being C-Circle negative.
Telomeric repeat loci. To find telomeric repeat loci we searched for tumor-specific
discordant paired-end reads, where one end was an extracted telomere read and the
other end was non-telomeric and uniquely mapped to a chromosome (mapping
quality >30). In 1 kb regions containing at least four discordant reads in the tumor
sample and none in the matching control, exact junction sites were defined by at
least three split reads. The split reads had to contain at least one TTAGGG repeat.
Regions with discordant read pairs in at least 15 control samples were excluded.
Finally, the junction sites were visualized using the Integrative Genomics Viewer
(IGV)62,63 to identify and remove remaining false positives. 1q42.2 hotspot region
was manually inspected to add automatically excluded telomeric repeat loci
(NBD158 and NBD137). The pipeline used to detect telomeric repeat loci is
available via Github [https://github.com/linasieverling/TelomereRepeatLoci].
RNA-sequencing. Using the Nucleo Spin RNA kit (Macherey Nagel) RNA was
isolated from fresh frozen tissue according to the manufacturers’ instructions.
mRNA was isolated using poly A selection with Dynabeads (Thermo Fisher). 100
bp paired sequencing was carried out using the Illumina Hiseq 2000 and Hiseq
4000. Alignment to the reference genome (1000 Genomes project phase 3 assembly
with decoy and PhiX contigs) was done using STAR Version 2.5.2b65 with the







15–chimSegmentReadGapMax 3–alignSJstitchMismatchNmax 5 −1 5
5–alignIntronMax 1100000–alignMatesGapMax 1100000–alignSJDBoverhangMin
3–alignIntronMin 20–clip3pAdapterSeq AGATCGGAAGAGCACACGTCTGAAC
TCCAGTCA–readFilesCommand gunzip -c. Sambamba version 0.6.566 was used
for merging and duplication marking. Bam files were filtered with SAM tools
version 1.3.167. Read counts per gene were obtained with featurecounts version
1.5.168 by counting reads over exon features using GENCODE 19 as a gene model.
Both reads of a paired fragment were used for counting and only unique align-
ments were considered by setting the quality threshold to 255. The read counting
was performed in an unstranded manner. The workflow used for RNA-sequencing
is available at [https://github.com/DKFZ-ODCF/RNAseqWorkflow]. For the cal-
culation of TPM expression values, genes on chromosomes X, Y, MT and rRNA
and tRNA genes were omitted when calculating total library abundance calcula-
tions to prevent library size estimation biases. Differential expression analysis was
performed using DESeq2 version 1.18.169 to find differences between samples with
chr1q42.2-1qter deletion and those without a specific deletion in this region.
chr1q42.2-1qter deletion was defined as reduced copy number compared to the
upstream neighboring segment. Low-count genes with less than 10 reads across the
entire cohort were excluded. Gender and sequencing location were included as
possible confounding variables. Filtered raw count data was used for the default
analysis including size factor estimation, dispersion estimation, negative binomial
generalized linear model fitting, and Wald statistics. Log fold change shrinkage was
applied. The results were filtered afterwards to include only genes from 230Mb to
the end of chromosome 1.
TERRA expression. To determine TERRA expression, RNA-sequencing reads
containing telomere repeats were extracted with TelomereHunter64 version 1.0.1
using a threshold of 14 telomere repeats per 100 bp read length and otherwise
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21247-8
14 NATURE COMMUNICATIONS |         (2021) 12:1269 | https://doi.org/10.1038/s41467-021-21247-8 | www.nature.com/naturecommunications
default settings. All extracted telomere reads were considered as TERRA reads
independently of the mapping position. To normalize for different library sizes, the
number of TERRA reads was divided by the total read count and multiplied by 1
million. (Note that RNA-sequencing was done using poly-A selection).
ATRX per exon normalized RNA expression. The paired-end RNA-sequencing
reads were aligned to human genome reference hg19 using STAR version 2.4.1
tool65 with restriction to only unique alignments. Gene expression counts per exon
were computed using corresponding DEXseq tool70 version 1.24.3 based on
adjusted GENCODE 19 annotation. The computed per exon counts from ATRX
were extracted and normalized using RPKM measurement via exon length. Subset
of formed exonic parts (EP 13, 16, 17, 23, 31, 37, 38) with no coverage variance
across samples was excluded from the initial gene model annotation for the main
heatmap generation. Genomic coordinates for the DEXseq ATRX exon model are
given in Supplementary Table 4.
Proteome analysis. Tumor samples were lysed with 2% SDS, 50 mM ammonium
bicarbonate buffer and complete mini EDTA-free Protease Inhibitor Cocktail.
Samples were homogenized at room temperature 15 s for 7 cycles with a 5 s pause
using FastPrep-24™ 5 G Homogenizer and heated to 95 °C for 5 min. Freeze–thaw
cycles were repeated seven times. Benzonase was added to each sample and the
lysate was clarified by centrifugation at 16 rcf for 30 min at 4 °C. Protein con-
centration was then measured using the Bio-Rad DC Protein assay. From each
sample, 50 µg of protein were taken in duplicate. Proteins were reduced with
10 mM DTT for 30 min and alkylated with 55 mM iodoacetamide for 30 min.
Wessel–Flügge precipitation was performed as previously described71. The
retrieved protein pellet was resuspended in 6 M Urea, 2 M Thiourea in 10 mM
HEPES (pH 8). Proteins were then digested with LysC for 2 h; samples were diluted
in 50 mM ammonium bicarbonate buffer to reach less than 2M urea before trypsin
was added for overnight digestion. The peptide solution was acidified and frac-
tionated by SCX on StageTips as described previously72. Samples were then
separated by reversed phase HPLC on a 2000 mm monolithic column and analyzed
online by high-resolution mass spectrometry on a Q Exactive plus mass instrument
as described previously73. The resulting raw files were analyzed using MaxQuant
software version 1.5.5.1 with LFQ quantification and ‘match between runs’ function74.
Data was searched against a Human Uniprot database (2014-10; [https://www.
uniprot.org/]) and common contaminants74 at a false discovery rate (FDR) of 1% at
both the peptide and protein level. The resulting text files were filtered to exclude
reverse database hits, potential contaminants, and proteins only identified by site.
Data was imputed by random draw from a normal distribution with default para-
meters: 0.3 width and 1.8 down shift. Proteins associated with telomere maintenance
and biology were identified using the TelNet database22 [https://malone2.bioquant.
uni-heidelberg.de/fmi/webd/TelNet].
ATRX/DAXX knockdown experiments and Western blot. NBL-S neuroblastoma
cells were cultured in RPMI media supplemented with 10% FBS, 100 U/ml peni-
cillin, and 100 µg/ml streptomycin. siRNAs were transfected in 6-well format using
Lipofectamine®RNAiMAX (Life Technologies) according to the manufacturer’s
instructions. NBL-S cells were transfected with siRNAs targeting DAXX or ATRX
as control at a final concentration of 25 nM. siRNA sequences are given in Sup-
plementary Table 2. NBL-S cells were harvested 96 h after transfection and cell
pellets were lysed in M-PER lysis buffer (Thermo Fisher). 30 µg of protein lysate
were run on NUPAGE 3–8% Tris-acetate gels (Thermo Fisher). Primary antibodies
were incubated overnight at 4 °C. ATRX antibody was obtained from Sigma
(HPA001906; rabbit polyclonal) and used at a dilution of 1:1000. DAXX antibody
was obtained from Abcam (ab32140; rabbit monoclonal E94) and used at a dilution
of 1:5000. Secondary anti-rabbit HRP (Dianova 111-035-144; goat polyclonal)
coupled antibody was used at a dilution of 1:2000. Vinculin-HRP coupled antibody
(clone 7F9, Santa Cruz sc73614) was used as loading control at a dilution of 1:1000.
A list of all antibodies is provided in Supplementary Table 3. Experiments were
done in three biological replicates. Western blot images were quantified using the
gel analysis function of Image J (version 1.51). P values were calculated using a
two-sided Student’s t-test with the function t.test in R.
Combined interphase FISH for MYCN and telomeres
NBD151. Tumor touch imprints or 5 µm frozen sections of primary tumors
mounted on microscopy glass slides were fixed with 4% Rotifix (Roth) for 10 min at
4 °C and FISH was performed using a telomere PNA-Cy3 FISH probe (Dako/Life
Technologies) according to the manufacturer’s instructions and a MYCN-digox-
igenin (dig) probe (BAC clone RP11-355H10). Briefly, slides were pretreated with
0.05% pepsin in 0.01 N HCl for 1 min at 37 °C, followed by dehydration (70%, 96%,
100% EtOH series). Probes were applied, denaturation was carried out at 80 °C for
5 min and hybridization at room temperature for 3 h. After immersion in 1xPBS,
slides were washed in standard saline citrate (SSC) containing 70% formamide at
42 °C for 15 min and twice with 0.1xSSC for 5 min. The MYCN-dig probe was
detected using a sheep polyclonal anti-dig-FITC antibody (dilution 1:100; Roche
11207741910). Slides were washed in PNA Wash-buffer (Dako) and dehydrated in
an EtOH series. Sections were counterstained and mounted with Vectashield
containing DAPI (Vector laboratories) and covered with glass coverslips. Images
were acquired using a Zeiss Axioplan2 microscope and the ISIS software version
5.7.4 (Metasystems).
Matching primary of NBI26. Amplification status of MYCN was determined as
described previously75 with MYCN Vysis LSI N-MYC (2p24) SpectrumGreen/
CEP2 SpectumOrange and Vysis LSI N-MYC Spectrum orange. Activation of ALT
was determined by identification of ALT-associated promyelocytic leukemia (PML)
nuclear bodies (APB) by immunofluorescence in combination with FISH using
Alexa-488-(TTAGGG)n PNA probes as described previously6. Images were
acquired using Leica DM 5550B fluorescent light microscope system at 63x reso-
lution. Full z-stacks were taken at 0.5 µm and projected using Cytovision software
(Version 7.6).
NBI5. Tumor touch imprints were fixed and labeled as previously described76.
Telomere labeling was done using the Telomere PNA FISH Kit/Cy3 (Agilent). For
MYCN FISH DNA from BAC clone RP11-355H10 was labeled with FITC-dUTP
by nick translation. Fluorescent images were captured with a Leica DMRA2
microscope equipped with a Leica DFC360 FX camera and analyzed with the Leica
CW 4000 FISH software.
Telomerase activity. Subset of the tumors was part of a previous publication1.
Telomerase activity was measured using the TeloTAGGG Telomerase PCR ELI-
SAPLUS Kit (Sigma Aldrich), which is a PCR-based telomeric repeat amplification
protocol (TRAP) enzyme-linked immunosorbent assay (ELISA) kit, according to
the manufacturer’s instructions. Approximately 10 mg of tissue were used
per tumor.
FACS analysis of tumors. FACS analysis of neuroblastoma tumors was done as
part of a previously published study77.
ChIP-sequencing. ChIP-sequencing was performed based on a combination of the
previously published protocols78,79, which is briefly summarized in the following.
Tumor tissue was cut in 30 µm slices and fixed with 1% formaldehyde for 10 min
followed by quenching with glycine for 5 min. Approximately 30 mg of tissue were
used for each IP. Tumor tissue was lysed by adding 120 µL lysis buffer (50 mM
Tris-HCl (pH 8.0), 10 mM EDTA, 1% SDS, protease inhibitor), homogenized using
a pestle, incubated on ice for 5 min and sonicated for 5 cycles in a Diagenode
Bioruptor Pico (30 s ON, 30 s OFF). After centrifugation (10 min, 12,000 rpm,
4 °C), the supernatant was transferred into a sonication tube (Diagenode). The
pellet was resuspended in 30 µL lysis buffer and centrifuged again. 150 µL of
mRIPA-I buffer without SDS (10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0),
500 mM NaCl, 0.1% Na-Deoxycholate, protease inhibitor) were added to the
combined supernatants and samples were sonicated for 40 cycles (30 s ON, 30 s
OFF). 220 µL mRIPA-I buffer without SDS were added and centrifuged (10 min,
12000 × g, 4 °C). Supernatant was kept and pellet resuspended in another 220 µL
mRIPA-I buffer without SDS. Centrifugation was repeated and supernatants
combined. 75 µL/IP magnetic protein G beads (Dynabeads Invitrogen) were
washed twice with binding/blocking buffer (PBS with 0.5% BSA and 0.5% Tween-
20). 3 µg of antibody were added together with 300 µL of binding/blocking buffer
and incubated for at least 1 h at room temperature while rotating. H3K36me3
(ab9050; rabbit polyclonal), K3K9me3 (ab8898; rabbit polyclonal), and H3K27ac
(ab4729; rabbit polyclonal) antibodies were obtained from Abcam. H3K27me3
antibody was purchased from Active Motif (39155; rabbit polyclonal). All anti-
bodies are listed in Supplementary Table 3. The beads were washed again with
blocking/binding buffer and sonicated chromatin was added and incubated over-
night at 4 °C while rotating. Beads were washed once with ice-cold RIPA buffer
(10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0), 140 mM NaCl, 0.1% SDS, 0.1%
Na-Deoxycholate, protease inhibitor), five times with ice-cold RIPA buffer (no
protease inhibitor), twice with ice-cold RIPA-500 (10 mM Tris-HCl (pH 8.0),
1 mM EDTA (pH 8.0), 500 mM NaCl, 0.1% SDS, 0.1% Na-Deoxycholate, 1%
Triton X-100), twice with ice-cold LiCl wash buffer (10 mM Tris-HCl (pH 8.0),
1 mM EDTA (pH 8.0), 250 mM LiCl, 0.5% NP-40, 0.5% Na-Deoxycholate), and
once with ice-cold 1xTE buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0)).
Samples were eluted in 50 µL of direct elution buffer (10 mM Tris-HCl (pH 8.0),
5 mM EDTA (pH 8.0), 300 mM NaCl, 0.5% SDS). 5% of the sonicated material
were used as input control and processed in parallel from this step onwards.
Samples were RNAse A treated (0.2 µg/µL) for 30 min at 37 °C. 2.5 µL proteinase K
(10 mg/mL) and 1 µL glycogen (20 mg/mL) were added and incubated for 2 h at
37 °C. Samples were inclubated at 65 °C overnight to reverse cross-linking. Pur-
ification was done using Agencourt Ampure XP beads (Beckman Coulter Geno-
mics) at a 2.3 ratio. Library preparation was done using the NEBNext End Repair
Module (NEB), NEBNext dA-Tailing Module (NEB), and NEBNext Quick Ligation
Module (NEB). High-Fidelity PCR Master Mix (NEB) was used for PCR amplifi-
cation and adapter addition. Libraries were size selected using AgencourtAmpure
XP beads (Beckman Coulter). Sequencing was done using Illumina HiSeq2000 50
bp single end sequencing.
ChIP-sequencing data analysis. ChIP-sequencing data was analyzed using a
custom pipeline implemented in Snakemake. Using the Trimgalore tool version 0.4
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[https://github.com/FelixKrueger/TrimGalore] reads were trimmed and subse-
quently data was aligned to the hg38 reference genome using Bowtie2 version 2.3.
Unmapped reads were not excluded from the bam files during alignment. Bamfiles
were processed using the deepTools2 suite80 version 3.0. Using bamCompare input
files were subtracted. Signal files (bigwig) were obtained using the SES method for
normalization. Peaks were called using MACS2 version 2.1 [https://github.com/
taoliu/MACS] for H3K27ac or SICER81 version 1.1 for H3K9me3, H3K27me3, and
H3K36me3. ChIP-sequencing workflow is available at [https://github.com/hdsu-
bioquant/chipseq_telomeres/]. Telomeric reads containing at least 8 telomeric
repeats per 100 bp read length were extracted in ChIP and input samples using
TelomereHunter64 with the option -rt 8 –rl. Number of telomeric reads was
normalized to the total number of mapped reads. Reads containing the canonical
SatII (ATTCCATTCGATTCCATTCG) and SatIII (ATTCCATTCCATTC-
CATTCCATTCCATTCC) sequence35 were extracted using Telomere Hunter64
version 1.0.1. Number of satellite reads was normalized to the total number of
mapped reads. Log2 enrichment of normalized telomeric/satellite reads in ChIP
was calculated relative to input files. Samples with a fraction of reads in peaks
below one were excluded from the analysis.
Tel log2ð Þenrichment ¼ log2 telomeric reads in IP=total mapped reads
telomeric reads in input=total mapped reads
 
SatII log2ð Þenrichment ¼ log2 SatII reads in IP=total mapped reads
SatII reads in input=total mapped reads
 
SatIII log2ð Þenrichment ¼ log2 SatIII reads in IP=total mapped reads
SatIII reads in input=total mapped reads
 
Statistics. Differences between various neuroblastoma subgroups in terms of tel-
omere content, telomeric repeat loci, enrichment of ChIP signals, TPM, and LFQ
expression values were tested with two-sided Wilcoxon rank-sum tests using R (R
Foundation for Statistical Computing, version 3.5.1 or 3.6.1). All boxplots were
generated using the function geom_boxplot() in the R package ggplot2 (version
3.2.0 or 3.3.1). Thus, all boxplots indicate the median value. The lower and upper
hinge of the boxplots correspond to the 25th and 75th percentiles. The upper/lower
whisker spans from the hinge to the largest/smallest value (values expanding a
distance of 1.5 x inter quartile range are not considered). Additionally, individual
samples are shown as jitter points. Dotplot showing quantification of ATRX pro-
tein levels after DAXX knockdown based on western blot images was done using
the function geom_dotplot() in the R package ggplot2 (version 3.3.1). Horizontal
line is representing the median value. P values for Western blot quantification were
calculated using a two-sided unpaired Student’s t-test in R with the function t.test.
P values for differential RNA expression analysis were calculated with Wald tests
within DESeq2 version 1.18.169. P values for differential protein expression analysis
were calculated with two-sided Student’s t-test statistics using Perseus software
version 1.5.5.382. Correlation analysis was performed using ggpubr (version 0.3.0)
or with the function cor in R. Enrichment analysis was tested by hypergeometric
test on gene symbols of significantly different proteins and mRNA determined for
this analysis by SAM-modified83 (S0= 0.01) Welch t-test were performed using R.
Multiple testing correction by Benjamini–Hochberg method was performed with
the R function p.adjust. Survival curves were generated using Kaplan Meier analysis
in the R package survminer (version 0.4.7). P values for survival analysis were
calculated using log rank tests. The optimal cut point to assess the prognostic
impact of the number of telomeric repeat loci and telomere content was deter-
mined using Maximally Selected Rank Statistics with the criteria that at least 20%
of the cases have to be in each group using the R package survminer (version 0.4.7).
Associations of C-Circle presence with clinical features like age, sex, stage, risk
classification was calculated using Fisher tests. Enrichment of TP53 pathway
mutations (TP53, CREBBP, ATM, ATR, CDKN2A, and MDM2) and PTPRD
mutations was calculated using a Fisher test comparing the occurrence in ALT-
positive compared to ALT-negative tumors. Enrichment of RAS pathway muta-
tions (HRAS, KRAS, NRAS, BRAF, RAF1, NF1, CDK4, CCND1) was calculated
using a Fisher test comparing their occurrence in ALT-positive tumors in the
discovery cohort compared to ALT-positive tumors in the INFORM cohort. HET
cases and relapse cases of the discovery cohort were excluded. A Fisher test was
used to calculate the enrichment of proteins mentioned in the Telnet database in
the differentially expressed proteins of ALT-positive tumors. Fisher tests were done
using R (version 3.6.1).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Whole genome sequencing, whole exome sequencing, ChIP-sequencing, RNA-
sequencing, and proteome data has been archived at the European Genome-phenome
Archive [https://www.ebi.ac.uk/ega/] and can be found under accession number
EGAS00001004349. Part of the whole genome and RNA-sequencing data was previously
published6 and is available under the accession number EGAS00001001308. The data is
deposited under controlled access. Data access can be obtained by contacting Frank
Westermann for EGAS00001004349 or Matthias Fischer for EGAS00001001308. Access
to data requires a data transfer agreement. mRNA and protein expression data are
available as datasets in the R2 database and can be interactively analyzed. mRNA
expression data can be found under the name “Tumor Neuroblastoma ALT -
Westermann − 144 - tpm - gencode19” [https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?
table=ps_avgpres_2010fwr144_gencode19]. Protein data can be found under the name
“Tumor Neuoblastoma ALT (Protein) – Westermann – 34 – LFQ - fw2010prot” [https://
hgserver1.amc.nl/cgi-bin/r2/main.cgi?table=ps_avgpres_fw2010prot34_fw2010prot]. All
functional SNVs, INDELs, SVs and copy number alterations (only amplification and
homozygous deletions) for all tumors in the discovery cohort are provided as
Supplementary Data 7–9. The remaining data are available within the Article,
Supplementary Information or available from the authors upon request. Source data are
provided with this paper.
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